Myc Proto Oncogene Protein Pipeline Review, H2 2019
Summary
Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC Myc cMyc protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz1 transcription factor and displacing the p300 coactivator, it inhibits expression of Miz1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a protooncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA overreplication.
Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 7 and 5 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Lymphoma, Breast Cancer, Hematological Tumor, Solid Tumor, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Burkitt Lymphoma, Chondrosarcoma, Colon Cancer, Glioblastoma Multiforme GBM, Hepatocellular Carcinoma, Leukemia, Lung Cancer, Metastatic Breast Cancer, Multiple Myeloma Kahler Disease, Neuroblastoma, NonSmall Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma and TCell Acute Lymphocytic Leukemia TCell Acute Lymphoblastic Leukaemia.
The latest report Myc Proto Oncogene Protein Pipeline Review, H2 2019, outlays comprehensive information on the Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC
The report reviews Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC targeted therapeutics and enlists all their major and minor projects
The report assesses Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope